IP Library Patent Application 17668744
Patent Application
App. No. 17/668,744

METHODS FOR PREVENTING OR TREATING MITOCHONDRIAL PERMEABILITY TRANSITION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/668,744
Abstract

The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p m ) and the total number of amino acid residues (r) wherein 3p m is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p t ) wherein 2 a is the largest number that is less than or equal to p t +1, except that when a is 1, p t may also be 1.

Claims (7)

1 - 16 . (canceled)

17 . An aromatic-cationic peptide for use in inhibiting cardiac stunning in cardiac tissue that is subjected to or recovering from ischemia in a subject in need thereof, wherein the aromatic-cationic peptide has the formula D-Arg-2′6′-Dmt-Lys-Phe-NH 2 .

18 . The peptide for use according to claim 17 , wherein the peptide is used in conjunction with the reperfusion of ischemic cardiac tissues.

19 . The peptide for use according to claim 18 , wherein the reperfusion of ischemic cardiac tissues comprises angioplasty, coronary artery bypass graft, or the use of thrombolytic drugs.

20 . The peptide for use according to claim 18 , wherein the peptide is applied to coronary stents.

21 . The peptide for use according to claim 17 , wherein the peptide is administered locally or systemically.

22 . The peptide for use according to claim 17 , wherein the peptide is administered intravenously, orally, topically, intranasally, intramuscularly, subcutaneously, transdermally, or iontophoretically.